In our institution, for example, we prefer to start with Lutathera for NETs if patients have significant extrahepatic disease, especially if symptomatic. For patients with liver-dominant disease, we find it reasonable to start with LDTs and leave Lutathera for a later disease stage when there is disease progression. Different institutions may follow different protocols and each case must be discussed in a tumor board to achieve consensus. It’s worth noting that patients with tumoral radiotracer uptake lower than that of the background liver (Krenning score 1–2) are unlikely to benefit from Lutathera treatment while tumors with higher uptake (Krenning score 3–4) are more likely to respond to treatment given higher receptor expression.
Radiotheranostics are a platform that combines the diagnostic and therapeutic aspects of oncology practice into one paradigm.
nuclear medicine fellowship, specifically, to learn more about radiotheranostics.
This led me to complete a nuclear medicine fellowship at the University of Iowa, followed by an interventional radiology fellowship at Harvard-BIDMC in Boston. I am currently a clinical assistant professor at the Medical College of Georgia, Augusta University, the medical director of the theranostics program and the program director of the integrated IR/DR residency.
The intersection of IR and radiotheranostics IR introduced revolutionary treatment options to the field of medical oncology.
The transarterial approach allowed for selective delivery of chemotherapy and radiation to tumors, resulting in increased drug delivery to target tumors while reducing undesirable systemic side effects. If the transarterial approach is combined with the highly targeted nature of radiotheranostics, then an excellent personalized therapeutic platform may evolve.
Many NETs patients have liver metastasis on presentation. As such, liver-directed therapies (LDTs), whether thermal ablation or transarterial therapies, are essential tools for managing these patients. As radiotheranostics become more available, IRs should consider whether their patients may benefit more from LDTs, radiotheranostics or both.
It seems like a simple question. However, it is a challenging one that requires familiarity with these treatment options. Until clear guidelines are available, interventional radiologists would need to use their best clinical judgment to decide, together with medical oncologists, which treatment option may be better to consider first.
Clinical trials are ongoing to investigate intra-arterial radiotheranostics therapies for metastatic NETs to the liver and for metastatic prostate cancer. If these trials demonstrate survival benefit of the intra-arterial approach over intravenous approach in select clinical scenarios, then interventional radiology will be expected to play a critical role in advancing the field in the near future. Currently, radiotheranostics are being administrated in most centers by authorized nuclear medicine physicians, but interventional radiologists highly interested in this field may need to get dedicated nuclear medicine training to be able to administer these radiotheranostics on a wider scale.
Where to find out more
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has a dedicated Radiopharmaceutical Therapy Central resource (therapy.
snmmi.org/snmmi-therapy) that provides valuable information for physicians interested in the clinical and research applications of radiotheranostics.
irq.sirweb.org | 31
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
